Stock listing

NASDAQ:ACXP Acurx Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Acurx Pharmaceuticals, Inc.

Follow Acurx Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ACXP

$1.04 USD +0.04 (+4.0%)

Close on Nov 20, 2026

Past year -73.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.02 – $1.12 USDNov 20, 2026
Volume
154,309 sharesNov 20, 2026
Market cap
$6.30M USDAt the close on Nov 20, 2026 · price × 6.06M shares outstanding
52-week range
$0.90 – $7.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$118,900 USDMedian day 82,532 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Acurx Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACXP · Home$1.04 USD+0.04 (+4.0%)154,309$1.11$1.12$1.02$1.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACXP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.04+0.04+4.0%$1.11$1.12$1.02154,309
$1.00+0.01+1.0%$1.03$1.03$0.9678,489
$0.99+0.055+5.9%$1.00$1.03$0.954232,223
$0.935-0.025-2.6%$1.00$1.04$0.90116,912
$0.96-0.025-2.5%$1.04$1.04$0.92223,447
$0.985-0.045-4.4%$1.05$1.06$0.98159,022
$1.03-0.01-1.0%$1.05$1.08$1.0398,551
$1.04-0.02-1.9%$1.06$1.09$1.0266,352
$1.060.000.0%$1.06$1.123$1.06118,739
$1.06+0.114+12.1%$1.01$1.08$1.01122,243
$0.946-0.084-8.2%$1.11$1.11$0.946188,458
$1.03+0.01+1.0%$1.07$1.076$1.016168,302
$1.02-0.05-4.7%$1.07$1.111$1.01206,417
$1.07+0.03+2.9%$1.08$1.12$1.045143,678
$1.04-0.03-2.8%$1.09$1.103$1.03563,193
$1.070.000.0%$1.06$1.11$1.0664,574
$1.07+0.01+0.9%$1.08$1.08$1.0561,179
$1.06-0.025-2.3%$1.08$1.096$1.0558,323
$1.085-0.05-4.4%$1.12$1.135$1.08164,135
$1.135-0.005-0.4%$1.135$1.14$1.1222,151
$1.14-0.01-0.9%$1.16$1.185$1.1426,544
$1.15+0.01+0.9%$1.18$1.18$1.1320,961
$1.140.000.0%$1.16$1.18$1.11568,303
$1.14+0.04+3.6%$1.14$1.146$1.1051,098
$1.10-0.07-6.0%$1.18$1.19$1.069164,832
$1.17+0.02+1.7%$1.20$1.219$1.15101,503
$1.15-0.05-4.2%$1.20$1.22$1.1587,573
$1.20-0.08-6.3%$1.29$1.29$1.2099,674
$1.28+0.01+0.8%$1.28$1.30$1.2580,819
$1.27+0.02+1.6%$1.24$1.28$1.2441,145
$1.25-0.05-3.8%$1.281$1.281$1.2474,937
$1.30-0.01-0.8%$1.32$1.33$1.2878,042
$1.310.000.0%$1.30$1.33$1.2842,200
$1.31+0.04+3.1%$1.25$1.36$1.25110,872
$1.27+0.01+0.8%$1.28$1.28$1.24582,492
$1.260.000.0%$1.27$1.295$1.2564,944
$1.26-0.045-3.4%$1.32$1.32$1.23130,517
$1.305-0.035-2.6%$1.38$1.38$1.27162,116
$1.34-0.02-1.5%$1.36$1.36$1.3352,785
$1.360.000.0%$1.38$1.38$1.35134,020
$1.36-0.01-0.7%$1.39$1.39$1.34548,071
$1.37+0.01+0.7%$1.36$1.385$1.3558,697
$1.36+0.03+2.3%$1.34$1.391$1.305156,188
$1.33-0.06-4.3%$1.39$1.41$1.31280,635
$1.390.000.0%$1.36$1.419$1.3657,399
$1.39+0.01+0.7%$1.386$1.41$1.3870,433
$1.38+0.025+1.8%$1.37$1.39$1.3661,268
$1.355-0.035-2.5%$1.39$1.40$1.3582,106
$1.39-0.01-0.7%$1.40$1.42$1.3884,352
$1.400.000.0%$1.41$1.41$1.3864,705
$1.40-0.01-0.7%$1.41$1.425$1.3858,784
$1.41-0.02-1.4%$1.413$1.43$1.4132,569
$1.43+0.01+0.7%$1.41$1.46$1.4188,565
$1.42+0.02+1.4%$1.40$1.42$1.3947,678
$1.40-0.03-2.1%$1.42$1.42$1.3951,590
$1.43+0.03+2.1%$1.41$1.44$1.4082,532
$1.40-0.05-3.4%$1.43$1.43$1.38109,675
$1.45+0.01+0.7%$1.44$1.45$1.40111,676
$1.44-0.02-1.4%$1.47$1.47$1.4269,740
$1.46+0.03+2.1%$1.43$1.479$1.4286,862
$1.43+0.02+1.4%$1.42$1.46$1.39146,082
$1.41+0.01+0.7%$1.41$1.445$1.4087,729
$1.40-0.07-4.8%$1.47$1.49$1.395132,653
$1.47+0.02+1.4%$1.45$1.53$1.4584,594
$1.45+0.01+0.7%$1.41$1.46$1.39132,202

Splits

1 split · NASDAQ:ACXP · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:ACXP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Acurx Pharmaceuticals, Inc. news

Acurx Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 124 in all · newest Nov 12, 2026 · oldest 2021
Calls
19 calls with a replay · 19 with a transcript · latest Nov 12, 2026
Decks
16 decks · latest Oct 20, 2025

Where Acurx Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACXP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ACXPBOATSUnited StatesUSD
gettex:3ZO0gettexGermanyEUR
LS Exchange:A41DXHLS ExchangeGermanyEUR
Frankfurt:3ZO0FrankfurtGermanyEUR
Lang & Schwarz:A41DXHLang & SchwarzGermanyEUR
Munich:3ZO0MunichGermanyEUR

Valuation

Price/book 0.9× against a median of 1.3×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$3.35M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.31

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Acurx Pharmaceuticals, Inc. · NASDAQ:ACXPUS$6.30M−US$3.35Mn/an/an/a0.9×n/a0.0×1.31
Aligos Therapeutics, Inc. · NASDAQ:ALGSUS$6.64M−US$12.55Mn/a−2.1×n/a0.6×n/a1.1×1.63
ZEO ScientifiX Inc. · OTC:ZEOXUS$6.51MUS$5.27Mn/a1.0×n/an/a−106.2%n/a0.54
FibroBiologics, Inc. · NASDAQ:FBLGUS$6.34MUS$5.17Mn/an/an/a3.5×n/a0.0×0.34
GT Biopharma, Inc. · NASDAQ:GTBPUS$6.33M−US$3.60Mn/an/an/a0.8×n/a0.0×1.57
Kyntra Bio, Inc. · NASDAQ:KYNBUS$6.32M−US$33.97Mn/a−6.4×n/an/a−326.0%n/a1.58
TrivarX Limited · ASX:TRIUS$6.11MUS$4.58Mn/an/an/a0.6×n/a0.0×n/a
Enveric Biosciences, Inc. · NASDAQ:ENVBUS$6.04MUS$429,455n/an/an/a1.1×n/a0.0×0.76
Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDBUS$6.03MUS$6.03Mn/a314×n/a5.4×n/a0.0×n/a
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Median of the othersUS$6.21MUS$3.16M1.0×1.3×−216.1%0.0×1.17

Forecasts

2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
17.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.02 · 2 analysts

Team and board

Officers

OfficerRole
David P. LuciPresident and Chief Executive Officer
Robert G. ShawahCo-Founder & Chief Financial Officer
Robert J. DeLucciaExecutive Chairman

Board

DirectorRole
Robert J. DeLucciaExecutive Chairman
Carl SailerDirector
David P. LuciPresident and Chief Executive Officer
Jack H. DeanDirector
James DonohueDirector
Joseph C. ScodariDirector
Thomas HarrisonDirector

Events

Calls

CallWhenStatus
Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2026 Earnings CallThu, Nov 12, 2026 · 4:00 PM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2026 Earnings CallFri, Aug 14, 2026 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2026 Earnings CallTue, May 12, 2026 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2025 Earnings CallFri, Mar 13, 2026 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2025 Earnings CallWed, Nov 12, 2025 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2025 Earnings CallTue, Aug 12, 2025 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2025 Earnings CallTue, May 13, 2025 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2024 Earnings CallTue, Mar 18, 2025 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2024 Earnings CallWed, Nov 13, 2024 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2024 Earnings CallFri, Aug 09, 2024 · 8:00 AM ETReplay
All 19 calls
CallWhenStatus
Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2024 Earnings CallWed, May 15, 2024 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2023 Earnings CallMon, Mar 18, 2024 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2023 Earnings CallMon, Aug 14, 2023 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2023 Earnings CallFri, May 12, 2023 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2022 Earnings CallTue, Aug 16, 2022 · 8:30 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2022 Earnings CallWed, May 11, 2022 · 8:30 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2022 Earnings CallWed, Mar 16, 2022 · 8:00 AM ETReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2021 Earnings CallTue, Aug 17, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−4.4%
Q2 2026Aug 13, 2026 · After close−5.7%
Q1 2026May 11, 2026 · After close−6.0%
Q4 2025Mar 13, 2026−4.0%
Q3 2025Nov 12, 2025 · Before open−10.8%
Q2 2025Aug 11, 2025 · After close−1.0%
Q1 2025May 12, 2025 · After close−3.8%
Q4 2024Mar 17, 2025 · Before open+2.6%
Q3 2024Nov 12, 2024 · After close−1.6%
Q2 2024Aug 8, 2024 · After close−1.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+7.7%
Q4 2023Mar 15, 2024 · After close−4.8%
Q3 2023Nov 13, 2023 · After close−2.9%
Q2 2023Aug 11, 2023 · After close−8.4%
Q1 2023May 12, 2023 · Before open−8.5%
Q4 2022Mar 15, 2023 · After close−1.5%
Q3 2022Nov 10, 2022 · After close+1.8%
Q2 2022Aug 12, 2022 · After close+3.7%
Q1 2022May 10, 2022 · After close−4.3%
Q4 2021Mar 16, 2022 · After close+1.3%

Open Events

Decks

DeckKindSlidesDate
IDWeek 2025Conference10 slidesOct 20, 2025
Investor Presentation (September 2025)Investor deck23 slidesSeptember 2025
Technical Presentation (June 2025)Technical10 slidesJun 5, 2025
Peggy Lillis Foundation Inaugural CDI Scientific Symposium 2024Conference19 slidesNovember 2024
8th International Clostridioides difficile Symposium (ICDS) 2024Conference15 slidesSep 17, 2024
Technical Presentation (September 2024)Technical16 slidesSeptember 2024
Anaerobe 2024Conference19 slidesJuly 2024
ESCMID 2024, BarcelonaConference13 slidesApr 20, 2024
IPO Roadshow (April 2024)IPO roadshow23 slidesApr 2, 2024
IDWeek 2023Conference10 slidesOct 12, 2023
All 16 decks
DeckKindSlidesDate
IDWeek 2023Conference14 slidesOctober 2023
World Antimicrobial Resistance Conference 2023Conference15 slidesSep 7, 2023
ECCMID 2023 Pipeline CornerConference11 slidesApr 15, 2023
ID Week 2022Conference17 slidesOctober 2022
IPO Roadshow (June 2021)IPO roadshow22 slidesJun 11, 2021
IDWeek 2019Conference13 slides2019

Open Decks

Financings

RaiseDate
Registered direct offering of shares of common stock (or pre-funded warrants) with concurrent unregistered short-term warrants
Closed: US$2.5M raised · US$3.03 a share · Warrants at US$2.78 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Apr 16, 2026
Warrant exercise of existing warrants exercised for shares of common stock
Announced: about US$2.67M · US$0.6 a share · Warrants at US$0.425 for 60 months
Use of proceeds: Working capital and general corporate purposes
Jun 17, 2025
Equity line of credit
Announced: raise
Buyers: Lincoln Park Capital (equity line of credit for up to $12 million of additional funding)
May 13, 2025
Registered direct offering of shares of common stock with unregistered short-term warrants
Closed: US$1.1M raised · US$0.4 a share · Warrants at US$0.4 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Mar 10, 2025
Registered direct offering of shares of common stock with unregistered warrants
Announced: about US$2.5M · US$1.015 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Jan 6, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$6.00 a share on Jun 24, 2021.

Price
US$6.00 a share
Shares offered
2,500,000 shares of common stock
Offering size
US$15 million
Underwriters' option
Up to 375,000 more shares
Listing
ACXP on the Nasdaq Capital Market
Underwriters
Alexander Capital, L.P., Network 1 Financial Securities, Inc. · In the order on the cover
Shares delivered
On or about Jun 29, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceApr 5, 2021
Filed publiclyMay 27, 2021
Amended onceJun 11, 2021
Shares registered with an exchangeJun 23, 2021
Declared effective by the SECJun 24, 2021
Final prospectus, with the priceJun 28, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Research and development1.83M5.40M6.04M4.75M2.03M2.20M3.51M
Selling, general and administrative6.26B8.70M8.53M7.34M208.3K2.40M2.42M
Operating income-8.09M-14.1M-14.6M-12.1M-12.9M-4.60M-5.93M
Depreciation and amortization14.1M14.6M12.1M66.5K4.60M5.93M
EBITDA0232224-12.8M00
Interest expense1.22K66.5K00
Income before tax-7.97M-14.1M-14.6M-12.1M-12.7M-4.60M-5.93M
Income tax-14.1B-14.6K0-66.5K0-5.93K
Net income-7.97M-14.1M-14.6M-12.1M-12.7M-4.60M-5.93M
Earnings per share, basic-5.32-17.45-1.15-1.12-1.49-0.74-12.43
Earnings per share, diluted-5.32-17.45-1.15-1.12-1.49-0.74

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents7.56M3.71M7.47M9.11M13.0M3.18M2.48M
Receivables48.4K51.1K129.2K
Current assets7.69M3.86M7.71M9.38M13.3M3.22M2.53M
Total assets7.69M3.86M7.71M9.38M13.3M3.22M2.53M
Accounts payable3.81K29.5K63.4K2.30K
Current liabilities2.42M3.24M3.04M2.06M843.9K472.6K1.71M
Long-term debt49.9K
Total debt66.5K
Total liabilities2.42M3.24M3.04M2.06M843.9K522.4K1.71M
Shareholders' equity5.27M615.1K4.67M7.32M12.4M2.70M819.9K
Shares outstanding2.35M851.5K14.5M11.6M10.2M11.6M477.1K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-6.79M-10.4M-9.80M-7.54M-5.01M-3.35M-3.99M
Capital spending00-50-300
Free cash flow-6.79M-10.4M-9.80M-7.54M-5.01M-3.35M-3.99M
Cash from financing10.6M6.62M8.16M3.70M14.8M4.04M4.46M
Share buybacks-1.04K0
Change in cash3.85M-3.77M-1.64M-3.85M9.78M692.1K470.2K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
8-K · Current reportNov 13, 2026Management or board changeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026Current reportSEC
8-K · Current reportOct 16, 2026Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveSep 18, 2026Other filingsSEC
424B3 · ProspectusSep 17, 2026Offer documentSEC
S-1 · Registration statementSep 8, 2026Offer documentSEC
ARS · Annual report to shareholdersSep 1, 2026Annual reportSEC
DEFA14A · Additional proxy materialSep 1, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
DEF 14A · Proxy statementSep 1, 2026Meeting noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
424B3 · ProspectusMay 12, 2026Offer documentSEC
424B3 · ProspectusMay 12, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 12, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 12, 2026Other filingsSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
CORRESP · Letter to the SECMay 7, 2026Other filingsSEC
CORRESP · Letter to the SECMay 7, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 7, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 7, 2026Other filingsSEC
S-1 · Registration statementMay 4, 2026Offer documentSEC
S-1 · Registration statementMay 4, 2026Offer documentSEC
DApr 29, 2026Other filingsSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
8-K · Current reportApr 16, 2026Material contractSEC
424B5 · ProspectusApr 16, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 9, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveFeb 12, 2026Other filingsSEC
424B3 · ProspectusFeb 11, 2026Offer documentSEC
CORRESP · Letter to the SECFeb 9, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 9, 2026Other filingsSEC
S-1 · Registration statementFeb 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 7, 2026Other filingsSEC
CORRESP · Letter to the SECJan 2, 2026Other filingsSEC
S-3/A · Registration statement, amendedDec 30, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
424B3 · ProspectusNov 10, 2025Offer documentSEC
S-1 · Registration statementOct 20, 2025Offer documentSEC
8-K · Current reportSep 22, 2025Current reportSEC
8-K · Current reportSep 19, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialAug 5, 2025Meeting noticeSEC
DEF 14A · Proxy statementAug 5, 2025Meeting noticeSEC
8-K · Current reportJul 31, 2025Current reportSEC
PRE 14A · Preliminary proxy statementJul 25, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveJul 24, 2025Other filingsSEC
CORRESP · Letter to the SECJul 21, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 21, 2025Other filingsSEC
8-K · Current reportJul 17, 2025Meeting outcomeSEC
S-1 · Registration statementJul 14, 2025Offer documentSEC
UPLOAD · Letter from the SECJul 14, 2025Other filingsSEC
S-3 · Registration statementJul 9, 2025Offer documentSEC
DJun 27, 2025Other filingsSEC
8-K · Current reportJun 20, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveMay 30, 2025Other filingsSEC
424B3 · ProspectusMay 29, 2025Offer documentSEC
ARS · Annual report to shareholdersMay 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 29, 2025Meeting noticeSEC
CORRESP · Letter to the SECMay 27, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 27, 2025Other filingsSEC
S-1 · Registration statementMay 21, 2025Offer documentSEC
DMay 20, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementMay 19, 2025Meeting noticeSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 15, 2025Other filingsSEC
CORRESP · Letter to the SECApr 10, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 10, 2025Other filingsSEC
S-1 · Registration statementApr 4, 2025Offer documentSEC
8-K · Current reportMar 28, 2025Current reportSEC
DMar 20, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 20, 2025Other filingsSEC
8-K · Current reportMar 18, 2025ResultsSEC
S-8 · Registration statement for employee plansMar 17, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 17, 2025Offer documentSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
8-K · Current reportMar 10, 2025Material contractSEC
424B5 · ProspectusMar 10, 2025Offer documentSEC
8-K · Current reportFeb 26, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 7, 2025Other filingsSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
CORRESP · Letter to the SECFeb 4, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 4, 2025Other filingsSEC
S-1 · Registration statementJan 31, 2025Offer documentSEC
DJan 17, 2025Other filingsSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
424B5 · ProspectusJan 7, 2025Offer documentSEC
8-K · Current reportJan 7, 2025Material contractSEC
424B3 · ProspectusJan 6, 2025Offer documentSEC
8-K · Current reportNov 13, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K · Current reportJun 17, 2024Meeting outcomeSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
RW · Request to withdraw a registrationApr 17, 2024Other filingsSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
FWP · Free writing prospectusApr 2, 2024Offer documentSEC
S-1/A · Registration statement, amendedMar 29, 2024Offer documentSEC
8-K · Current reportMar 18, 2024ResultsSEC
S-1 · Registration statementMar 18, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 15, 2024Offer documentSEC
10-K · Annual reportMar 15, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
8-K · Current reportNov 15, 2023Material contractSEC
424B5 · ProspectusNov 15, 2023Offer documentSEC
8-K · Current reportNov 14, 2023ResultsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 3, 2023Current reportSEC
8-K · Current reportOct 2, 2023Current reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
424B3 · ProspectusJul 13, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 11, 2023Other filingsSEC
CORRESP · Letter to the SECJul 6, 2023Other filingsSEC
UPLOAD · Letter from the SECJul 5, 2023Other filingsSEC
S-1 · Registration statementJun 29, 2023Offer documentSEC
8-K · Current reportJun 20, 2023Meeting outcomeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
424B3 · ProspectusMay 18, 2023Offer documentSEC
424B5 · ProspectusMay 17, 2023Offer documentSEC
8-K · Current reportMay 17, 2023Material contractSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
ARS · Annual report to shareholdersApr 27, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2023Meeting noticeSEC
8-K · Current reportMar 16, 2023ResultsSEC
S-8 · Registration statement for employee plansMar 15, 2023Offer documentSEC
10-K · Annual reportMar 15, 2023Annual reportSEC
4 · Change in ownershipFeb 24, 2023Insider tradeSEC
4 · Change in ownershipFeb 24, 2023Insider tradeSEC
4 · Change in ownershipFeb 24, 2023Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2023Big-stake noticeSEC
8-K · Current reportNov 14, 2022ResultsSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
424B3 · ProspectusSep 23, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 23, 2022Other filingsSEC
CORRESP · Letter to the SECSep 20, 2022Other filingsSEC
UPLOAD · Letter from the SECSep 19, 2022Other filingsSEC
S-1 · Registration statementSep 14, 2022Offer documentSEC
8-K · Current reportAug 15, 2022ResultsSEC
10-Q · Quarterly reportAug 12, 2022Quarterly reportSEC
4 · Change in ownershipJul 29, 2022Insider tradeSEC
4 · Change in ownershipJul 29, 2022Insider tradeSEC
4 · Change in ownershipJul 29, 2022Insider tradeSEC
424B5 · ProspectusJul 25, 2022Offer documentSEC
8-K · Current reportJul 25, 2022ResultsSEC
EFFECT · Notice that a registration is effectiveJul 12, 2022Other filingsSEC
CORRESP · Letter to the SECJul 7, 2022Other filingsSEC
UPLOAD · Letter from the SECJul 7, 2022Other filingsSEC
S-3 · Registration statementJul 1, 2022Offer documentSEC
8-K · Current reportJun 7, 2022Meeting outcomeSEC
8-K · Current reportMay 11, 2022ResultsSEC
10-Q · Quarterly reportMay 10, 2022Quarterly reportSEC
DEFA14A · Additional proxy materialApr 25, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2022Meeting noticeSEC
8-K · Current reportMar 17, 2022ResultsSEC
S-8 · Registration statement for employee plansMar 16, 2022Offer documentSEC
10-K · Annual reportMar 16, 2022Annual reportSEC

This page holds 200 of 248 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Acurx Pharmaceuticals, Inc.’s releases · as of Nov 12, 2026

Common shares
6,058,135
Fully diluted
6,058,135

Fully diluted

LineSharesAs of
Common shares6,058,135Nov 12, 2026

Warrants and options

Lot
Warrants · US$2.78 · expire about Apr 2028
Warrants · US$0.40 · expire about Mar 2027

Share count over time

CountShares
Nov 12, 20266,058,135
Sep 30, 20265,879,237

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard47,3040.78%US$59,603Sep 30, 2026
Geode Capital26,2970.43%US$33,134Sep 30, 2026
XTX Topco Ltd24,1200.40%US$30,391Sep 30, 2026
Lanark Financial, Inc.15,2000.25%US$19,152Sep 30, 2026
Cambridge Investment Research Advisors, Inc.15,0000.25%US$19,000Sep 30, 2026
Prospect Financial Services LLC13,2850.22%US$16,740Sep 30, 2026
Jane Street12,9600.21%US$16,330Sep 30, 2026
Hrt Financial LP10,0070.17%US$12,000Sep 30, 2026
Morgan Stanley7,5000.12%US$9,450Sep 30, 2026
Tower Research Capital LLC (TRC)3,7840.06%US$4,767Sep 30, 2026
All 18 holders
HolderSharesOf the companyValueAs of
Wells Fargo2,3000.04%US$2,898Sep 30, 2026
Westside Investment Management, Inc.1,6500.03%US$2,079Sep 30, 2026
UBS278<0.01%US$351Sep 30, 2026
Osaic Holdings, Inc.100<0.01%US$126Sep 30, 2026
BlackRock60<0.01%US$76Sep 30, 2026
Group One Trading LLC10<0.01%US$13Sep 30, 2026
SBI Securities Co., Ltd.6<0.01%US$8Sep 30, 2026
Caitong International Asset Management Co., Ltd5<0.01%US$6Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund31,0990.51%US$48,203Jun 30, 2026
Fidelity Extended Market Index Fund16,2500.27%US$32,175May 31, 2026
Fidelity Series Total Market Index Fund2,9780.05%US$5,896May 31, 2026
Fidelity Total Market Index Fund1,0010.02%US$1,982May 31, 2026
Fidelity Nasdaq Composite Index Fund146<0.01%US$289May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC9.99%1.29MJun 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Thomas Harrison
Other companies: Agenus Inc. (Director · Since at least Aug 7, 2024); Advanced Flower Capital Inc. (Director · Since at least Mar 18, 2021); Zynerba Pharmaceuticals Inc (Director · Aug 4, 2015 – Jun 6, 2018 · Past); Fifth Street Asset Management Inc (Director · Oct 29, 2014 – Dec 8, 2017 · Past); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); rVue Holdings Inc (Director · Sep 19, 2013 – Dec 3, 2013 · Past); Epocrates Inc (Director · Feb 1, 2011 – Mar 12, 2013 · Past); Omnicom Group Inc. (Chrmn/CEO Divers. Agency Serv. · May 4, 2006 – Mar 31, 2010 · Past); Morgans Hotel Group Company (Director · Feb 13, 2006 – May 17, 2012 · Past)
Director · Since at least Jun 24, 2021
David P. Luci
Other companies: Enveric Biosciences, Inc. (Director · Feb 8, 2018 – Aug 20, 2018 · Past); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); Abeona Therapeutics Inc. (Director · Jan 4, 2007 – Nov 2, 2009 · Past); Bioenvision Inc (EVP & General Counsel · Feb 28, 2006 – Jul 10, 2007 · Past)
President and CEO, Director · Since at least Jun 24, 2021
Jack H Dean
Other companies: PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past)
Director · Since at least Jun 24, 2021
Joseph C. Scodari
Other companies: OptiNose (Director · Jun 6, 2019 – Jun 8, 2022 · Past)
Director · Since at least Jun 24, 2021
Carl SailerDirector · Since at least Jun 24, 2021
Jack H. DeanDirector · Since at least Nov 4, 2026
James DonohueDirector · Since at least Jun 24, 2021
Robert G. ShawahChief Financial Officer · Since at least Feb 23, 2024
Robert J. DeLucciaExecutive Chairman · Since at least Jul 27, 2022

Open People

Log in to ask 6ix AI your own questions about Acurx Pharmaceuticals, Inc.